01 Jul 2009
Total Voting Rights
July 1, 2009 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical
company, in accordance with DTR 5.6.1 of the FSA’s Disclosure and Transparency Rules, notifies
the market of the following:
At close of business on June 30, 2009, Shire plc's issued voting share capital consisted of
560,283,142 ordinary shares with a nominal value of 5 pence. Each ordinary share carries one
voting right. Shire plc does not hold any shares in Treasury.
The above figure (560,283,142) may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their interest in, or a change to
their interest in, Shire plc under the FSA's Disclosure and Transparency Rules.
Tony Guthrie
Deputy Company Secretary
For further information please contact:
Investor Relations
Cléa Rosenfeld (Rest of the World) +44 1256 894 160
Eric Rojas (North America) +1 617 551 9715
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on
meeting the needs of the specialist physician. Shire focuses its business on attention deficit
hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as
well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s
in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong
intellectual property protection and global rights. Shire believes that a carefully selected and
balanced portfolio of products with strategically aligned and relatively small-scale sales forces will
deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.
Did you know...
You can sign up to receive email and SMS alerts so that you can keep up to speed with our latest news.
Did you know...
We donated over $35,000 in
outdated laboratory
equipment to local
schools?
